Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participationCARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase 2 clinical t ...

PRESS RELEASEParis, 26th June 2025 Ramsay Générale de Santé Board of Directors appoints Natalie Davis as Chairman of the Board At its meeting today, the Board of Directors announced the appointment of Natalie Davis as Chairman of the Board of Directors. She succeeds Craig McNally, who is stepping down from this position, which he has held since 2017. "On behalf of the entire Ramsay Santé Group team, I would like to offer Craig McNally our sincerest thanks for his eight years of exemplary commitment as Cha ...

Former Accenture Global Commerce Head & Tata Digital founder and CTO Sauvik Banerjjee Named PresidentMove Follows Rezolve Ai’s $70 Million ARR Break-Through and Comes as Meta buys a 49% stake in Ai-services player Scale AI for $14.3 Billion NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Rezolve Ai (NASDAQ: RZLV), the company reinventing retail through real-time AI-driven consumer engagement, today announced the creation of Rezolve Ai Professional Services, a new global growth platform formed in direct response ...

Core Insights - Upexi, Inc. plans to tokenize its SEC-registered shares using the Opening Bell platform from Superstate, enhancing shareholder access and leveraging the Solana ecosystem [1][2][3] - The company currently holds 735,692 SOL, reflecting an 8% increase from 679,677 SOL reported on May 28 [3] Company Overview - Upexi specializes in the development, manufacturing, and distribution of consumer products and has diversified into the cryptocurrency space [4] - The company is recognized as the largest Solana treasury company, aiming to acquire and hold as much SOL as possible [2] Tokenization and Technology - Opening Bell, launched in May 2025, allows companies to issue tokenized public equity via blockchain, initially utilizing Solana [3] - Tokenization is expected to provide benefits such as 24/7 trading, real-time settlement, and broadened investor access without impacting existing shareholder rights [7] Leadership and Strategy - Upexi is led by CEO Allan Marshall, who emphasizes the company's commitment to the Solana ecosystem and the potential for long-term value creation through intelligent capital markets strategies [2][3] - The partnership with Superstate, a leading SEC-registered transfer agent, is aimed at harnessing Solana's speed and scalability [2]

THORNTON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Ascent Solar Technologies (Nasdaq: ASTI) (“Ascent” or the “Company”), the leading U.S. innovator in the design and manufacture of featherweight, flexible, and durable CIGS thin-film photovoltaic (PV) solutions, announced today that the company is commencing work on a Collaborative Agreement Notice (CAN) with NASA Marshall Space Flight Center (MSFC) and support from NASA Glenn Research Center (GRC) to efficiently advance capabilities for receiving beamed pow ...

Extensive enhancements to tax technology portfolio empowers businesses with greater agility and accuracyKING OF PRUSSIA, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced a series of new certified integrations and solution enhancements that expand connectivity across ERP, e-commerce, procurement and financial systems. These updates reflect Vertex’s continued focus on simplifying and automating gl ...

Leviate joins Vaunt with 13 aircraft, including 6 HondaJets, reinforcing member demand for premium light jets ATLANTA, GA, June 26, 2025 (GLOBE NEWSWIRE) -- Volato Group, Inc. (the “Company” or “Volato”) (NYSE American: SOAR) today announced that Leviate Air Group has joined its Vaunt platform as an approved third-party operator, adding 13 additional aircraft to the network—including 6 HondaJets. The partnership strengthens Vaunt’s core offering in the light jet category and expands access to one of the mos ...

GRAND CAYMAN, Cayman Islands, June 26, 2025 (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (Nasdaq: OXBR) (“Oxbridge Re”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary SurancePlus, today announced its participation during the Ethereum Community Conference (EthCC), to be held in Cannes, France, June 30–July 3, 2025. The event brings together blockchain builders, institutional investors, and capital allocators from around the world to expl ...

Core Insights - ZyVersa Therapeutics, Inc. has initiated patient recruitment for its VAR 200 Phase 2a clinical study targeting diabetic kidney disease (DKD) [1][2] - VAR 200 is designed to address renal lipotoxicity by removing excess lipids from the kidneys, which is a significant factor in the progression of kidney diseases [3][7] - The study aims to evaluate the efficacy and safety of VAR 200 in patients with type 2 diabetes and DKD, with preliminary data expected in the second half of 2025 [7] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases with significant unmet medical needs [8] - The company is advancing a therapeutic pipeline that includes VAR 200 and another program targeting inflammation [8] Clinical Study Details - The VAR 200 Phase 2a trial will be an open-label study conducted at one to two US sites, enrolling an adequate number of subjects to complete eight [2][7] - The primary efficacy endpoint is the percent change from baseline to week 12 in urinary albumin to creatinine ratio, with treatment lasting 12 weeks followed by a four-week follow-up [2][7] Drug Mechanism and Indications - VAR 200, a Cholesterol Efflux Mediator™, is an injectable drug that aims to reduce renal lipid accumulation, which damages the kidney's filtration system [3][5] - Preclinical studies have shown that VAR 200 can reduce cholesterol and lipid levels, protect against renal injury and fibrosis, and improve proteinuria in various kidney disease models [4][7] Future Prospects - The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS), with plans to expand indications based on the results of the ongoing trials [5][7] - The initiation of patient recruitment is considered a key milestone in the development of VAR 200, with the potential to be a first-in-class treatment for kidney disease [7]

Company in full compliance for continued listingMIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the ...